NASDAQ · FTRE
Healthcare · Biotechnology
$21.29
Down-$1.85 (-7.97%)
Updated Oct 31, 2026, 6:01 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · FTRE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
FTRE closed at $21.29 after 21 trading sessions, up 6.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $23.295 | $23.51 | $20.70 | $21.29 | 2.87M |
| Oct 29, 2026 | $23.63 | $23.79 | $22.405 | $23.135 | 4.95M |
| Oct 28, 2026 | $24.36 | $26.16 | $24.30 | $25.88 | 3.59M |
| Oct 27, 2026 | $23.725 | $24.52 | $23.50 | $24.43 | 1.97M |
| Oct 26, 2026 | $23.63 | $24.14 | $23.63 | $23.83 | 1.04M |
| Oct 23, 2026 | $23.92 | $24.048 | $23.4241 | $23.63 | 1M |
| Oct 22, 2026 | $23.95 | $24.835 | $23.24 | $23.92 | 1.99M |
| Oct 21, 2026 | $22.45 | $24.37 | $22.302 | $24.06 | 2.48M |
| Oct 20, 2026 | $22.55 | $23.55 | $22.305 | $22.78 | 2.38M |
| Oct 19, 2026 | $22.49 | $23.04 | $22.38 | $22.42 | 1.65M |
| Oct 16, 2026 | $23.04 | $23.135 | $21.86 | $22.49 | 1.9M |
| Oct 15, 2026 | $21.93 | $23.07 | $21.63 | $22.745 | 2.91M |
| Oct 14, 2026 | $20.45 | $22.15 | $20.25 | $21.34 | 2.94M |
| Oct 13, 2026 | $21.11 | $21.215 | $20.60 | $20.92 | 767.67K |
| Oct 12, 2026 | $20.84 | $21.3118 | $20.675 | $21.00 | 1.24M |
| Oct 9, 2026 | $20.37 | $21.005 | $20.16 | $20.84 | 931.31K |
| Oct 8, 2026 | $20.14 | $20.455 | $19.78 | $20.37 | 1.96M |
| Oct 7, 2026 | $20.38 | $21.11 | $20.24 | $20.56 | 2.25M |
| Oct 6, 2026 | $21.99 | $23.51 | $20.73 | $20.78 | 2.65M |
| Oct 5, 2026 | $20.00 | $21.20 | $19.855 | $21.11 | 2.27M |
| Oct 2, 2026 | $19.58 | $20.05 | $19.09 | $20.00 | 1.19M |
The latest Smart Investors Daily articles mentioning FTRE.
Company
Market Activity
Research & News
FTRE research
Company profile and research snapshot.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Citigroup | Buy | — |
| Oct 30, 2026 | Truist Securities | Buy | — |
| Oct 30, 2026 | Barclays | Overweight | — |
| Oct 30, 2026 | Evercore ISI Group | Outperform | — |
| Oct 20, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 26, 2026
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 23, 2026
Fortrea (FTRE) demonstrates robust technical momentum, recently hitting a new 52-week high. Shares are up nearly 120% over the past year. FTRE maintains a 100% “Buy” technical opinion from Barchart. I view FTRE as a compelling opportunity due to its attractive valuation, strong growth prospects, and improving profitability. Today’s Featured...
Yahoo · Oct 22, 2026
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in AustraliaHighlights Collaboration aims to accelerate precision oncology research in AustraliaCombines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) programTogether, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-dr
Benzinga · Oct 22, 2026
HighlightsCollaboration aims to accelerate precision oncology research in AustraliaCombines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FTRE.
